4.5 Article

Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain

Journal

ACS MEDICINAL CHEMISTRY LETTERS
Volume 12, Issue 4, Pages 603-609

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00684

Keywords

Macrodomain; SARS-CoV-2; remdesivir; ADP-ribosylation; structure based design

Funding

  1. Goethe University Frankfurt under the Goethe-Corona-Fonds program
  2. SGC
  3. AbbVie [1097737]
  4. Bayer AG
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Eshelman Institute for Innovation
  8. Genentech
  9. Genome Canada through Ontario Genomics Institute [OGI-196]
  10. EU/EFPIA/OICR/McGill/KTH/Diamond
  11. Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN) [875510]
  12. Janssen
  13. Merck KGaA (EMD in Canada)
  14. Merck KGaA (EMD in U.S.)
  15. Merck & Co (MSD outside Canada)
  16. Merck & Co (MSD outside U.S.)
  17. Pfizer
  18. Sao Paulo Research Foundation-FAPESP
  19. Takeda
  20. Wellcome [106169/ZZ14/Z]
  21. Fraunhofer Internal Programs [Anti-Corona 164-600014]
  22. Deutsche Forschungsgemeinschaft (DFG, Heisenberg-Professur) [PR1405/7-1]

Ask authors/readers for more resources

The nsP3 macrodomain is crucial in regulating the host immune response during SARS-CoV-2 infection by recognizing and removing posttranslational ADP-ribosylation sites. Targeting this protein domain could provide a therapeutic strategy for combating virus pandemics. Crystal structures complexed with diverse nucleotides, small molecules, and nucleotide analogues, including active metabolites of remdesivir, provide valuable insights for inhibitor development.
The nsP3 macrodomain is a conserved protein interaction module that plays essential regulatory roles in the host immune response by recognizing and removing posttranslational ADP- ribosylation sites during SARS-CoV-2 infection. Thus targeting this protein domain may offer a therapeutic strategy to combat current and future virus pandemics. To assist inhibitor development efforts, we report here a comprehensive set of macrodomain crystal structures complexed with diverse naturally occurring nucleotides, small molecules, and nucleotide analogues including GS-441524 and its phosphorylated analogue, active metabolites of remdesivir. The presented data strengthen our understanding of the SARS-CoV-2 macrodomain structural plasticity and provide chemical starting points for future inhibitor development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available